Arbutus Biopharma Invited to Speak at Inaugural RNA-Based Therapeutics & Vaccines Summit Asia, Showcasing mRNA Platform, Cancer Vaccines, and Novel Immunotherapies

Nov 11, 2025 16:41 CST Updated 16:41

Abogen

Nucleic Acid Drug Developer

Dr. Ying Bo, Founder, Chairman and CEO of Abogen, was invited to attend the event held in Incheon, South Korea from November 18th to 20th.The First RNA-Based Therapeutics & Vaccines Summit Asia。

The theme of the conference is"Accelerating Asia’s Progress in RNA Therapeutics & Vaccines: Focusing on Precision Delivery, Safety Enhancement and Manufacturing Capacity to Advance Clinical and Commercial Readiness", aiming to build a comprehensive communication platform for the entire industry, gathering emerging forces in Asia that are rapidly rising in fields such as mRNA, saRNA, circRNA, and siRNA, to jointly explore development strategies to promote the regional success of RNA drugs.

This conference brings together many well-known pharmaceutical and biotech companies from around the world, such as Pfizer, Merck KGaA, Meiji Seka Pharma, the International Vaccine Institute (IVI), and the Coalition for Epidemic Preparedness Innovations (CEPI). Over 80 senior executives and research experts will share in-depth breakthrough research data, innovative achievements, and typical case studies, jointly advancing the clinical and commercialization process of RNA therapy drug candidates.

At the conference, Dr. Ying Bo will serve as a member of the Scientific Advisory Board, joining scientists and industry leaders from around the world to discuss the broad prospects of RNA therapies advancing into clinical and market applications. He will also act as a keynote speaker to share the platform advantages of Abogen’s “mRNA+LNP” and the latest clinical progress of its mRNA cancer vaccine.

Abogen Sharing Session

Keynote Speech

Subject:Unlocking Recent Clinical Progress of mRNA-Based Vaccines & B-Cell Depletion Therapies

Time:November 19, 2025, 9:00 AM (UTC+9)

Summary:

① Showcase the unique advantages of Abogen's mRNA+LNP platform;

② Share Clinical Data and Latest Results of mRNA Cancer Vaccines;

③ Advance the preclinical and clinical development of mRNA-based T cell engagers and targeting.

CEO Leadership Think Tank Forum

CEO Leaders Think Tank

Subject:Accelerating the Next Wave of RNA-Based Therapeutics & Vaccines to Develop Safe & Efficacious Drugs to Commercial Reality

Time:November 19, 2025, 14:20 (UTC+9)

Summary:

① What Opportunities, Targets, and Applications Could Lead to Clinical Success for Future RNA Therapies and Vaccines?

② How to Develop an RNA Platform and Reduce Its Risks in the Highly Competitive APAC Market?

③ What are the core challenges in scientific R&D and pipeline strategy management for 2025/26?

As a one-stop platform that integrates cutting-edge science and collaborative exchange, this conference will comprehensively showcase the latest advancements in RNA technology from basic research to production, manufacturing, and commercialization. It covers several key areas such as epidemic prevention and control, personalized cancer vaccines, and protein replacement therapies for rare diseases, with the aim of promoting cross-disciplinary collaboration and expanding industry networks. The deep involvement of Abogen Biosciences also highlights its leading position in the global RNA innovation field.

For more information, please visit the official website:

https://rnatherapeutics-vaccines-asia.com/

Nobel Laureate Leads | Abogen Biosciences Invited to Attend 2025 Vaccine and RNA Therapeutics Research Forum to Discuss the Future of RNA Innovation

Shining in Boston | Abogen Biosciences Honored with Pieter Cullis Award at the 4th LNP Formulation and Process Development Summit

About Us

Abogen Biosciences (referred to as "Abogen") is an innovative biopharmaceutical company specializing in the research and development of messenger ribonucleic acid (mRNA) drugs. The company possesses industry-leading, proprietary mRNA and nanodelivery technology platforms and is one of the few mRNA drug R&D enterprises in China with complete value chain capabilities, covering all aspects from mRNA design, formulation development to large-scale production. The company has established a rich product pipeline.Covering multiple fields such as tumor immunology, autoimmune diseases, and infectious disease prevention and treatment.